The nonsteroidal anti-inflammatory drug sulindac reverses obesity-driven immunosuppression and triple-negative breast cancer progression

Michael F. Coleman, Shannon B. McDonell, Lydia K. Eisenbeis, Emily N. Devericks, Jobin Chandi, Om Dave, Jane Pearce, Sylvia Wang, M Cody, Ximena M. Bustamante-Marin, Elaine M. Glenny, Erika T. Rezeli, Alyssa J. Cozzo, Ciara H. O’Flanagan, Brooke E Bathon, Saame Raza Shaikh, Ginger L. Milne, Michael K. Wendt, Nadia A. Lanman, Dorothy Teegarden, Stephen D. HurstingBreast 2025 · DOI

TL;DR

Obesity significantly worsens triple-negative breast cancer (TNBC) by suppressing the immune system within the tumor microenvironment. This study shows that the common anti-inflammatory drug sulindac can reverse these obesity-induced immune defects and slow tumor growth and metastasis, even without causing weight loss. This suggests sulindac could be a promising, accessible therapeutic for obese patients with TNBC.

What Problem Does This Paper Address?

Obesity is a major risk factor for developing and progressing several cancers, including triple-negative breast cancer (TNBC), a particularly aggressive form with poor prognosis. While weight loss is known to mitigate these risks, it's often difficult to achieve and maintain due to cost, accessibility, and lifestyle challenges. The underlying mechanisms by which obesity promotes TNBC include chronic low-grade inflammation and a weakened anti-tumor immune response within the tumor microenvironment (TME). Specifically, obesity impairs the ability of immune cells like T cells and macrophages to recognize and attack cancer cells. This paper aims to identify an accessible intervention that can counteract these obesity-driven immune suppressions and slow TNBC progression, even in the absence of significant weight loss.

Methods

The researchers employed a multi-pronged approach using preclinical models:

  • Preclinical Models: They used diet-induced obese (DIO) mice and normoweight control mice, implanting them with different triple-negative breast cancer cell lines (E0771, metM-Wntlung, metM-Wntliver).
  • Pharmacological Intervention: Sulindac, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits COX1 and COX2 enzymes, was administered orally via diet.
  • Tumor Growth and Metastasis Assessment: Tumor volume, mass, and the presence of lung micrometastases were measured to evaluate the drug's impact.
  • Transcriptomic Profiling:
    • Bulk RNA Sequencing: This was used to analyze the overall gene expression patterns in tumors from different groups (control, obese, obese + sulindac) to identify broad changes in immune and metabolic pathways.
  • Single-Cell RNA Sequencing (scRNAseq): This powerful technique allowed for the detailed analysis of individual cell types within the tumor microenvironment (cancer cells, T cells, myeloid cells like macrophages). This enabled the researchers to pinpoint how obesity and sulindac affected specific cell populations and their functions.
  • Gene Set Enrichment Analysis (GSEA): Used to identify biological pathways and processes that were significantly altered in response to obesity and sulindac treatment.
  • T-cell Receptor (TCR) Sequencing: To assess the diversity and repertoire of T cells, which is crucial for effective anti-tumor immunity.
  • Cell Viability and Migration Assays: In vitro experiments were conducted to test the direct effects of sulindac and other drugs on cancer cell behavior.

Datasets

The study utilized publicly available datasets for cell line gene expression analysis (GEO accession GSE98703). The primary transcriptomic data generated in this study (bulk and scRNAseq) are available in GEO under accession numbers GSE294944 and GSE294999, respectively.

Key Insights and Ideas

  • Obesity's Immune Suppression is Reversible by NSAIDs: The most striking finding is that sulindac, a common NSAID, can effectively counteract the immunosuppressive effects of obesity on the tumor microenvironment, restoring anti-tumor immunity.
  • Sulindac Works Independently of Weight Loss: A critical insight is that sulindac's beneficial effects on tumor growth and metastasis occur without significantly altering body weight or composition. This makes it a potentially valuable intervention for individuals who cannot achieve substantial weight loss.
  • Reprogramming Tumor Cell Metabolism: Sulindac appears to shift tumor cells towards oxidative phosphorylation, a more efficient metabolic pathway that may contribute to reduced tumor growth and improved immune function.
  • Restoring T-cell Diversity is Key: Obesity significantly reduces the diversity of T-cell receptors (TCRs) in the tumor, limiting the immune system's ability to recognize and attack cancer. Sulindac treatment restores this crucial T-cell diversity.
  • TAMs are Central Players: Tumor-associated macrophages (TAMs) are shown to be significantly affected by obesity, with sulindac restoring their ability to present antigens, a critical step in initiating an immune response.

Key Results

  • Sulindac treatment abrogated obesity-accelerated tumor growth and metastasis in multiple TNBC models.
  • This effect was achieved without significant changes in body weight or composition.
  • Transcriptomic analysis revealed that obesity suppressed immune-related gene signatures (including antigen presentation) in the TME, and sulindac treatment restored these.
  • scRNAseq showed sulindac reprogrammed tumoral metabolism towards oxidative phosphorylation and restored antigen presentation machinery in TAMs.
  • Sulindac reversed obesity-driven reduction in T cell receptor diversity within the TME.

Limitations and Future Work

  • Preclinical Models: The study was conducted in preclinical mouse models. While informative, these findings need to be validated in human clinical trials.
  • Prophylactic vs. Therapeutic Use: The study modeled prophylactic NSAID use (before tumor establishment) in an at-risk population. The efficacy of initiating sulindac treatment after TNBC diagnosis remains to be investigated.
  • Generalizability of NSAIDs: While sulindac showed promise, further evaluation of other NSAIDs and their specific mechanisms in the context of obesity and TNBC is warranted.
  • Clinical Translation: The authors emphasize that these protective effects observed in preclinical studies need to be validated in clinical studies to assess the potential of sulindac or other NSAIDs as adjuvant therapies for obese women with TNBC.

Summary updated

Abstract

Obesity affects over 40% of women in the US and increases the risk and progression of several cancers, including triple-negative breast cancer (TNBC), in part through chronic low-grade inflammation and impaired antitumor immunity. While weight loss can reverse obesity-driven cancer risk, cost and other factors limit the accessibility of effective weight loss interventions. This study investigated whether sulindac, a nonsteroidal anti-inflammatory drug (NSAID), could mitigate obesity-driven TNBC progression. Using multiple preclinical models, we demonstrate that sulindac treatment abrogates obesity-accelerated tumor growth and metastasis without affecting body weight or composition. Bulk transcriptomic profiling revealed obesity-driven suppression of immune-related gene signatures in the tumor microenvironment (TME)—including antigen presentation—while sulindac treatment restored these signatures. Single-cell RNA sequencing identified sulindac-mediated reprogramming of tumoral metabolism toward oxidative phosphorylation and restoration of antigen presentation machinery in tumor-associated macrophages. Sulindac also reversed obesity-driven reduction in T cell receptor diversity within the TME. We conclude that sulindac treatment remodels the TME and restores obesity-associated impairments of immunosurveillance, offering a potentially accessible intervention to limit obesity-driven TNBC progression. We demonstrate that NSAIDs, which are generally safe, cheap, and readily available, limit the burden of obesity-driven TNBC preclinically, warranting further evaluation as a targeted clinical intervention.
BibTeX
@inproceedings{coleman2025nonsteroidal,
  author = {Michael F. Coleman and Shannon B. McDonell and Lydia K. Eisenbeis and Emily N. Devericks and Jobin Chandi and Om Dave and Jane Pearce and Sylvia Wang and M Cody and Ximena M. Bustamante-Marin and Elaine M. Glenny and Erika T. Rezeli and Alyssa J. Cozzo and Ciara H. O’Flanagan and Brooke E Bathon and Saame Raza Shaikh and Ginger L. Milne and Michael K. Wendt and Nadia A. Lanman and Dorothy Teegarden and Stephen D. Hursting},
  title = {{The nonsteroidal anti-inflammatory drug sulindac reverses obesity-driven immunosuppression and triple-negative breast cancer progression}},
  booktitle = {Breast},
  year = {2025},
  doi = {10.1186/s13058-025-02134-2},
}
Figure